Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42160443 adjunctive therapy dose-ranging study in osteoarthritis pain
2009-009856-19Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing JNJ-42160443 dose-ranging adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoints: Change from baseline to end of 12-week double-blind efficacy phase in average osteoarthritis-related pain intensity score, Average pain intensity scores at the end of Weeks 4 and 8 and over the entire double-blind efficacy phase and 1 more. Started Oct 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2009-009856-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009856-19.